Multi-mechanism secondary-prevention polypill

Notes

original target text: Multi-mechanism secondary-prevention polypill (aspirin/statin/ACE-inhibitor)

This mechanism refers to a fixed-dose combination therapy—commonly called a polypill—that brings together three drug classes with distinct, complementary actions used after a cardiovascular event such as a heart attack: an antiplatelet agent (aspirin), a lipid-lowering agent (a statin), and a blood-pressure-lowering agent (an ACE inhibitor, which blocks the renin-angiotensin-aldosterone system). The biological rationale for combining them is that atherosclerotic cardiovascular disease is driven by several independent risk factors simultaneously—platelet-mediated clot formation, elevated cholesterol driving plaque buildup, and elevated blood pressure straining vessel walls. Rather than modulating a single pathway, this approach addresses three of the major modifiable drivers of recurrent events at once. In secondary prevention—treating patients who have already had a cardiovascular event and are at high risk of another—simplifying three previously separate medications into a single pill is intended to improve how consistently patients take their medication, since regimen complexity is a well-recognized cause of missed doses. The disease context is broad: coronary artery disease, prior myocardial infarction, and stroke are the settings where reducing platelet aggregation, LDL cholesterol, and blood pressure together is expected to lower the risk of subsequent ischemic events.